Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Knopp Biosciences

  • Michael Bozik, Knopp Biosciences

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for inflammatory and neurological diseases of high unmet need. Knopp’s clinical-stage small molecule, dexpramipexole, is entering Phase 3 clinical studies in hypereosinophilic syndrome and Phase 2 clinical studies in eosinophilic asthma. Knopp’s preclinical Kv7 platform is directed to small molecule treatments for neonatal epileptic encephalopathy, other rare epilepsies, tinnitus, and neuropathic pain. The Company is looking to complete a crossover financing in the first quarter of 2019.

  • Date:Tuesday, February 12
  • Time:11:15 AM - 11:30 AM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23424
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Gain Investment Community Exposure
  • Company Website:http://knoppbio.com/about/
  • Company HQ City:Pittsburgh
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$166 million
  • Year Founded:2004
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:dexpramipexole
  • Development Phase of Primary Product:Phase III
Speakers
Michael Bozik
Knopp Biosciences
Back